TORONTO and HAIFA, Israel, Aug. 15, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (NRX:CA), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”) is pleased to announce significant ...
Supported by Scientific Evidence Showing Tissue Repair Quality of Company’s ExosomesTORONTO and HAIFA, Israel, Dec. 12, 2025 ...
PranaX Corporation, a pioneer in exosome-based regenerative wellness, proudly announces the appointment of Phillip Maderia as its new Chief Executive Officer. With over three decades of leadership in ...
TORONTO and HAIFA, Israel, Sept. 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (NRX:CA) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a ...
TORONTO and HAIFA, Israel, Feb. 05, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (“NurExone” or the “Company”) is ...
cell-derived exosomes in large scale bioreactors in partnership with the French Blood Establishment (EFS) with unprecedented yields The disruptive, proprietary technology developed by EVerZom offers a ...
Pandorum Technologies, a clinical-stage regenerative medicine company building a next-generation platform for programmable tissue regeneration, today announced a strategic collaboration with Hyderabad ...
Alzheimer’s disease (AD) is the most common form of dementia affecting approximately 55 million people worldwide. In a new study published in Alzheimer’s and Dementia titled, “Familial Alzheimer’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback